Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression

NCT04826510 | Unknown Phase 4

• 1 other identifier: 3.0
• Study Type: interventional
• Target: 189
• Locations: 1 country
• Sites: 1

Brief Summary

Bipolar disorder, a type of mood disorder that occurs in various forms, such as depression, mania, hypomania or irregularity.According to the World Health Organization mental health survey, the lifetime prevalence of bipolar disorder is 2.4%; the 12-month prevalence was 1.5%. The lifetime incidence in Shenzhen was 1.5%, and the 12-month incidence was 1.1%. In another study in Hong Kong, the 12-month prevalence of bipolar I, II, and "soft" II was 1.4%, 0.5%, and 1.8%, respectively. Due to endocrine effects, bipolar disorder is more common in women than men, and mainly occurs in late adolescence and early adulthood, with an early trend. An investigation involving 23 countries around the world found that the average age of onset of bipolar disorder was 25 years old, and the low age group (17.24±3.20 years old) accounted for 41.7%. Another study in the United States showed that the average age of onset of bipolar disorder was 20 years old, and the low age group (14.5±4.9 years old) accounted for 63%. With the improvement of medical level, the diagnosis rate of bipolar disorder is getting closer to the true prevalence rate. Without active treatment, the symptoms of bipolar disorder, especially depression, will accompany the patients for a long time. The quality of life of patients is seriously affected. The safety of piperopilon hydrochloride has been widely recognized from pre-market clinical research to post-market clinical practice. A total of a clinical study involving 1191 patients showed that the incidence of side effects from long-term use of piperopilone was 21.3%, and the main side effects were mild in the nervous and digestive systems. In addition, it has been reported that piperopirone is also safe and effective for adolescents.Therefore, the investigators designed this study to explore the atypical antipsychotic drug piperopirone as a monotherapy or in combination with mood stabilizer.Clinical efficacy and safety of lithium acid in the treatment of depressive episodes in adolescents with bipolar disorder, and its improvement in cognitive function were assessed.The goal is to evaluate the efficacy and safety of piperopilone hydrochloride tablets in the treatment of bipolar depressive episode in adolescents.

Conditions

Depressive Disorder

Outcome Measures

Primary Outcomes (2)

• Clinical Global Impression Scale-Bipolar Disorder Scale (CGI-BP-S) score

  The investigators adopt the clinical General Impression Scale - Bipolar Disorder Scale (CGI-BP-S) score to analyze the scores of the subjects in different periods.

  Change from baseline at 2,4,8 week.

• Hamilton Depression Scale (HAMD-17) score

  The investigators adopt the Hamilton Depression Scale (HAMD-17) score to judge the subjects' depression. Starting points: Hamilton Depression Scale (HAMD-17)) ≥2, clinical remission: Hamilton Depression Scale (HAMD-17)) \<7.

  Change from baseline at 2,4,8 week.

Secondary Outcomes (4)

• Young's Manic Rating Scale (YMRS) score

  Change from baseline at 2,4,8 week.

• Montreal Cognitive Assessment Scale (MoCA) score

  Change from baseline at 8 week.

• Wisconsin Card Sorting Test (WCST-128) score

  Change from baseline at 8 week.

• WISC score for Children

  Change from baseline at 8 week.

Study Arms (3)

Lithium carbonate group

ACTIVE COMPARATOR

Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.

Drug: Lithium Carbonate Pill

Perospirone hydrochloride group

EXPERIMENTAL

The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.

Drug: Perospirone hydrochloride tablets

Lithium carbonate + perospirone hydrochloride group

EXPERIMENTAL

The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.

Drug: Lithium carbonate + perospirone hydrochloride

Interventions

Perospirone hydrochloride tablets DRUG

The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.

Perospirone hydrochloride group

Lithium carbonate + perospirone hydrochloride DRUG

The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.

Lithium carbonate + perospirone hydrochloride group

Lithium Carbonate Pill DRUG

Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.

Lithium carbonate group

Eligibility Criteria

• Age: 12 Years - 18 Years
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Outpatients or inpatients who met the diagnostic criteria of DSM-5 or ICD-10 for depressive episode of bipolar disorder.
• Willing to participate in clinical research and sign informed consent
• ≤ age ≤ 18
• HAMD-17 score ≥ 17; HAMD-17 item 1 (depression) ≥ 2, and YMRS ≤ 12
• Physical examination, laboratory examination, vital signs and 12 lead ECG showed that the physical condition was stable. If any test results are beyond the normal range, they can be included only if they are judged to be abnormal or deviated from the normal values but have no clinical significance or belong to reasonable conditions in the study population. Such decisions must be recorded in the subject's original file and signed by the researcher

You may not qualify if:

• Besides bipolar disorder, the diagnosis includes schizophrenia, schizophrenic affective disorder, schizoid disorder, depression, dissociation disorder, borderline personality disorder, material dependence, autism, organic mental disease, etc
• Other conditions except bipolar disorder were diagnosed, such as schizophrenia, schizophrenic affective disorder, schizophrenia like disorder, depression, dissociation disorder, borderline personality disorder, material dependence, autism, organic mental disease, etc. according to the judgment of the researcher, the patient is at risk of suicide or injury to others, or HAMD-17 item 3 Score ≥ 3, or attempted suicide in the past six months
• Patients with rapid circulation type;
• Those who had suffered from serious heart, liver, brain, lung, kidney and other serious diseases in the past or at present, and the researchers considered that they were not suitable for the study;
• The results of Biochemistry, hematology, electrocardiogram or urine test were not within the normal value range of the laboratory at the time of screening, and had clinical significance according to the judgment of the researchers (except for the abnormal indexes of reasonable condition in the research population, such as abnormal blood glucose and blood lipid indexes);
• The subjects received electroconvulsive therapy (ECT) within 6 months before enrollment;
• There was a history of malignant tumor or complications;
• Known allergy history or complications to test drug or ingredient (with previous history of allergic reaction caused by drug, rash, urticaria, etc.);
• Pregnant and lactating women and patients unable to take appropriate contraceptive measures during the trial period;
• Patients with previous suicidal behavior or existing strong suicidal tendency and patients with serious excited and aggressive behavior.

Sponsors & Collaborators

• Shanghai Mental Health Center: lead

Study Sites (1)

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, 200030, China

RECRUITING

MeSH Terms

Conditions

Depressive Disorder

Interventions

Lithium Carbonate

Condition Hierarchy (Ancestors)

Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Carbonates; Alkalies; Inorganic Chemicals; Carbonic Acid; Carbon Compounds, Inorganic; Lithium Compounds

Study Officials

• Yiru Fang, professor

  Shanghai Mental Health Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yiru Fang, professor

CONTACT

18017311133; yirufang@aliyun.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: Subjects will be randomly assigned to the lithium carbonate group, piperopirone hydrochloride group or the lithium carbonate + Piperopirone hydrochloride group after obtaining the corresponding random number according to the order of inclusion. According to the random centers, the lithium carbonate group: piperopirone hydrochloride group: lithium carbonate + Piperopirone hydrochloride group was 1:1:1
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The study is expected in the nine and clinical study of cooperative unit to carry out clinical research network, each is expected to include subjects about 21 cases (7 cases of lithium carbonate group, pp horse of the 7 cases, hydrochloric acid hydrochloric acid lithium carbonate + pp ROM horse lung group of 7 cases), with 189 recruit subjects (lithium carbonate group 63 examples, hydrochloric acid pp ROM horse lung group 63 examples, lithium carbonate + pp hydrochloride horse lung group 63 examples. The study is expected to be completed within two years.

Study Record Dates

• First Submitted: January 31, 2021
• First Posted: April 1, 2021
• Study Start: November 25, 2020
• Primary Completion: June 30, 2021
• Study Completion: June 30, 2021
• Last Updated: April 1, 2021

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, CSR
• Time Frame: start from 2021.6.30,last for 2years
• Access Criteria: the cooperative partners

Locations

CN (1)